Denmark-based multinational pharmaceutical company Novo Nordisk will be making available in the Philippines within this year ...

Bob Powell: Well, Wegovy can no longer be used for weight loss reasons under Medicare. And here to talk with me about that is Jae Oh, author of Maximize Your Medicare. Jae, what's up? Jae Oh ...

Compounded versions of weight-loss and diabetes medications made by smaller pharmacies and sold without FDA approval can no longer be legally produced or sold. HealthDay News — A federal deadline ...

Wegovy and Zepbound, which both sell for a list ... or the medication is sold in a vial rather than a prefilled injector pen — but doctors and patients say the changes are long overdue.

Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide (brand name Wegovy) in a 72-week clinical trial. The randomized, controlled trial — called ...

It’s a rather strange side effect of GLP-1 weight-loss medications – which include Ozempic, Wegovy, and Mounjaro – and one that I’ve experienced personally (even though I stopped taking ...

The "Semaglutide Market Size, Share & Trends Analysis Report by Product (Ozempic, Wegovy, Rybelsus), Application (Type 2 Diabetes Mellitus, Obesity), Route of Administration, Distribution Channel, ...

Novo Nordisk A/S is selling its blockbuster weight-loss drug Wegovy to new patients at $199 for the first month as easy access to cheaper copycats comes to an end. The one-time offer — available ...

Novo Nordisk’s Wegovy has a list price of $1,350 per month in the US. Credit: Karen Roach via Shutterstock. Evernorth, the pharmacy benefits unit for health insurer giant Cigna, has reached a deal ...

President Trump on Tuesday blasted former President Biden, vowing to look into the use of the autopen during his presidency days after his predecessor announced he was diagnosed with prostate cancer.

NEW YORK (Reuters) -Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S. drugs regulator clamps down on mass production of ...